    Matthew Harbaugh | Mallinckrodt plc | ZoomInfo.com


Insider Trading - Harbaugh Matthew K - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Harbaugh Matthew K





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Common stock purchase or sale:



TransactionDate
ReportedDate
Company
Symbol
InsiderRelationship
SharesTraded
AveragePrice
TotalAmount
SharesOwned
Filing




2016-05-10Purchase
2016-05-114:10 pm
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
500
$59.37
$29,684
56,036(Direct)
View


2016-02-09Purchase
2016-02-1008:47 am
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
1,300
$63
$81,900
55,383(Direct)
View


2015-12-03Purchase(A)
2015-12-071:18 pm
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
260
$74.05
$19,252
46,055(Direct)
View


2015-12-03Purchase
2015-12-0709:01 am
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
500
$73.8
$36,902
46,295(Direct)
View


2015-06-01Sale
2015-06-025:28 pm
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
22,106
$128.6
$2,843,818
69,099(Direct)
View




 (A) Indicate amendment filing.
 Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2017-01-04Tax Withholding
2017-01-066:12 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KExec. VP & CFO
724
$53.19
75,329(Direct)
View


2017-01-02Option Award
2017-01-048:42 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KExec. VP & CFO
10,864
$0
76,053(Direct)
View


2017-01-02Tax Withholding
2017-01-048:42 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KExec. VP & CFO
4,334
$49.82
76,053(Direct)
View


2017-01-02Option Award
2017-01-048:42 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KExec. VP & CFO
13,293
$0
76,053(Direct)
View


2017-01-02Option Award
2017-01-048:42 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KExec. VP & CFO
1,718
$0
76,053(Direct)
View


2017-01-02Option Award
2017-01-048:42 pm
2018-01-032027-01-03
Mallinckrodt Plc
MNK
Harbaugh Matthew KExec. VP & CFO
74,675
$51.73
76,053(Direct)
View


2017-01-02Option Award
2017-01-048:42 pm
2021-01-032027-01-03
Mallinckrodt Plc
MNK
Harbaugh Matthew KExec. VP & CFO
63,397
$51.73
76,053(Direct)
View


2016-12-03Tax Withholding
2016-12-0608:22 am
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KExec. VP & CFO
297
$53.61
54,512(Direct)
View


2016-07-01Tax Withholding
2016-07-064:07 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
1,460
$61.84
54,618(Direct)
View


2016-01-02Tax Withholding
2016-01-055:46 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
669
$74.63
54,010(Direct)
View


2016-01-02Option Award
2016-01-055:46 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
7,575
$0
54,010(Direct)
View


2016-01-02Option Award
2016-01-055:46 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
809
$0
54,010(Direct)
View


2016-01-02Option Award
2016-01-055:46 pm
2017-01-042026-01-04
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
49,508
$72.61
54,010(Direct)
View


2015-12-03Tax Withholding
2015-12-044:48 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
426
$72.2
45,795(Direct)
View


2015-12-01Tax Withholding
2015-12-024:42 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
1,009
$71.48
46,190(Direct)
View


2015-06-01Exercise
2015-06-025:28 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
3,166
$34.5
69,099(Direct)
View


2015-06-01Exercise
2015-06-025:28 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
14,951
$31.12
69,099(Direct)
View


2015-06-01Exercise
2015-06-025:28 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
19,500
$33.67
69,099(Direct)
View


2015-06-01Exercise
2015-06-025:28 pm
2013-12-012019-11-30
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
3,166
$34.5
69,099(Direct)
View


2015-06-01Exercise
2015-06-025:28 pm
2013-06-282020-11-30
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
14,951
$31.12
69,099(Direct)
View


2015-06-01Exercise
2015-06-025:28 pm
2013-06-282021-11-30
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
19,500
$33.67
69,099(Direct)
View


2015-02-01Tax Withholding
2015-02-035:40 pm
N/AN/A
Mallinckrodt Plc
MNK
Harbaugh Matthew KSr. VP & CFO
127
$106
31,373(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 28 Jul 2017 21:54:16 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  















Matthew Harbaugh - SVP and CFO of Mallinckrodt Pharmaceuticals




















Home







About Us

Core Strengths

Executive Team

Mark Trudeau
Meredith Fischer
Raymond Furey
Matthew Harbaugh
Michael-Bryant Hicks
Ron Lloyd
Hugh O'Neill
Gary Phillips, M.D.
Steven Romano, M.D.
Dr. Frank Scholz
Ian Watkins



Board of Directors

Mark Trudeau
Angus Russell
David Carlucci
Diane Gulyas
Joann Reed
Joseph Zaccagnino
Kneeland Youngblood
Martin Carroll
Melvin Booth
Virgil Thompson


Our Story
Inclusion and Diversity
Partnering
Blog
Patient Stories








Products







Research


Science & Technology

Pipeline



Research & Development

Clinical Trials
Formulation & Drug Delivery Technologies



Medical Affairs

Investigator-Initiated Research
Ongoing Investigator-Initiated Studies











Responsibility


Community Outreach

Mallinckrodt Community Giving
Philanthropy Contacts


Quality, Environment, Health and Safety

Responsible Use

Healthcare Issues
Programs
Red Flags
Medication Disposal


Sustainability
Pledge on Drug Pricing & Innovation
Interactions with Healthcare Professionals
Expanded Access Program for Investigational Drugs









Investor Relations

Analyst Coverage
Annual Reports
Calendar of Events
Corporate Governance
Historical Data on Acquired Companies
Information Request
Presentation Documents
SEC Filings
Supplemental Financial Information








News & Media






Careers






Contact Us























Search






Contact Us
News & Media
Font Size










Home







About Us

Core Strengths

Executive Team

Mark Trudeau
Meredith Fischer
Raymond Furey
Matthew Harbaugh
Michael-Bryant Hicks
Ron Lloyd
Hugh O'Neill
Gary Phillips, M.D.
Steven Romano, M.D.
Dr. Frank Scholz
Ian Watkins



Board of Directors

Mark Trudeau
Angus Russell
David Carlucci
Diane Gulyas
Joann Reed
Joseph Zaccagnino
Kneeland Youngblood
Martin Carroll
Melvin Booth
Virgil Thompson


Our Story
Inclusion and Diversity
Partnering
Blog
Patient Stories








Products







Research


Science & Technology

Pipeline



Research & Development

Clinical Trials
Formulation & Drug Delivery Technologies



Medical Affairs

Investigator-Initiated Research
Ongoing Investigator-Initiated Studies











Responsibility


Community Outreach

Mallinckrodt Community Giving
Philanthropy Contacts


Quality, Environment, Health and Safety

Responsible Use

Healthcare Issues
Programs
Red Flags
Medication Disposal


Sustainability
Pledge on Drug Pricing & Innovation
Interactions with Healthcare Professionals
Expanded Access Program for Investigational Drugs









Investor Relations

Analyst Coverage
Annual Reports
Calendar of Events
Corporate Governance
Historical Data on Acquired Companies
Information Request
Presentation Documents
SEC Filings
Supplemental Financial Information








News & Media






Careers






Contact Us























Matthew Harbaugh









About Us
Core Strengths


Executive Team

Mark Trudeau
Meredith Fischer
Karen Sheehy
Matthew Harbaugh
Michael-Bryant Hicks
Ron Lloyd
Hugh O'Neill
Gary Phillips, M.D.
Steven Romano, M.D.
Dr. Frank Scholz
Ian Watkins




Board of Directors

Melvin Booth
Mark Trudeau
David Carlucci
J. Martin Carroll
Diane Gulyas
JoAnn Reed
Angus Russell
Kneeland Youngblood, M.D.
Joseph Zaccagnino


Our Story


Partnering




Suppliers

Supplier Diversity
Suppliers & Sustainability
Conflict Minerals Policy
Supplier Inquiry Form




News & Media
Blog
Patient Stories






Careers at Mallinckrodt
Community Outreach
Investor Relations










        Matthew HarbaughExecutive Vice President and Chief Financial Officer





Matthew Harbaugh is executive vice president and chief financial officer at Mallinckrodt Pharmaceuticals. He has executive responsibility for finance, procurement and information technology. Mr. Harbaugh is a member of Mallinckrodt’s executive committee.
Mr. Harbaugh has more than 20 years of experience in controllership, corporate finance, business development, financial planning and analysis, and investor relations.
Previously, Mr. Harbaugh served as the chief financial officer and interim president of the pharmaceuticals division of Covidien. He has worked as a lead finance executive at Cerberus Capital Management, L.P., a New York-based private equity firm. He also spent nearly 10 years at Monsanto, where he held several positions, including corporate finance director, investor relations, and finance director/chief financial officer for the company’s southern Argentine/Chilean and Canadian operations via two expatriate assignments.
Mr. Harbaugh holds a bachelor’s degree in finance from Saint Louis University and an MBA from Northwestern University.
Back












Building On Our Heritage
Nearly 150 years of quality, integrity and service.

Learn More






Our Culture
From philanthropic efforts to advocacy initiatives, we are living our hallmarks throughout our communities.

Learn How



























Matthew Harbaugh - SVP and CFO of Mallinckrodt Pharmaceuticals




















Home







About Us

Core Strengths

Executive Team

Mark Trudeau
Meredith Fischer
Raymond Furey
Matthew Harbaugh
Michael-Bryant Hicks
Ron Lloyd
Hugh O'Neill
Gary Phillips, M.D.
Steven Romano, M.D.
Dr. Frank Scholz
Ian Watkins



Board of Directors

Mark Trudeau
Angus Russell
David Carlucci
Diane Gulyas
Joann Reed
Joseph Zaccagnino
Kneeland Youngblood
Martin Carroll
Melvin Booth
Virgil Thompson


Our Story
Inclusion and Diversity
Partnering
Blog
Patient Stories








Products







Research


Science & Technology

Pipeline



Research & Development

Clinical Trials
Formulation & Drug Delivery Technologies



Medical Affairs

Investigator-Initiated Research
Ongoing Investigator-Initiated Studies











Responsibility


Community Outreach

Mallinckrodt Community Giving
Philanthropy Contacts


Quality, Environment, Health and Safety

Responsible Use

Healthcare Issues
Programs
Red Flags
Medication Disposal


Sustainability
Pledge on Drug Pricing & Innovation
Interactions with Healthcare Professionals
Expanded Access Program for Investigational Drugs









Investor Relations

Analyst Coverage
Annual Reports
Calendar of Events
Corporate Governance
Historical Data on Acquired Companies
Information Request
Presentation Documents
SEC Filings
Supplemental Financial Information








News & Media






Careers






Contact Us























Search






Contact Us
News & Media
Font Size










Home







About Us

Core Strengths

Executive Team

Mark Trudeau
Meredith Fischer
Raymond Furey
Matthew Harbaugh
Michael-Bryant Hicks
Ron Lloyd
Hugh O'Neill
Gary Phillips, M.D.
Steven Romano, M.D.
Dr. Frank Scholz
Ian Watkins



Board of Directors

Mark Trudeau
Angus Russell
David Carlucci
Diane Gulyas
Joann Reed
Joseph Zaccagnino
Kneeland Youngblood
Martin Carroll
Melvin Booth
Virgil Thompson


Our Story
Inclusion and Diversity
Partnering
Blog
Patient Stories








Products







Research


Science & Technology

Pipeline



Research & Development

Clinical Trials
Formulation & Drug Delivery Technologies



Medical Affairs

Investigator-Initiated Research
Ongoing Investigator-Initiated Studies











Responsibility


Community Outreach

Mallinckrodt Community Giving
Philanthropy Contacts


Quality, Environment, Health and Safety

Responsible Use

Healthcare Issues
Programs
Red Flags
Medication Disposal


Sustainability
Pledge on Drug Pricing & Innovation
Interactions with Healthcare Professionals
Expanded Access Program for Investigational Drugs









Investor Relations

Analyst Coverage
Annual Reports
Calendar of Events
Corporate Governance
Historical Data on Acquired Companies
Information Request
Presentation Documents
SEC Filings
Supplemental Financial Information








News & Media






Careers






Contact Us























Matthew Harbaugh









About Us
Core Strengths


Executive Team

Mark Trudeau
Meredith Fischer
Karen Sheehy
Matthew Harbaugh
Michael-Bryant Hicks
Ron Lloyd
Hugh O'Neill
Gary Phillips, M.D.
Steven Romano, M.D.
Dr. Frank Scholz
Ian Watkins




Board of Directors

Melvin Booth
Mark Trudeau
David Carlucci
J. Martin Carroll
Diane Gulyas
JoAnn Reed
Angus Russell
Kneeland Youngblood, M.D.
Joseph Zaccagnino


Our Story


Partnering




Suppliers

Supplier Diversity
Suppliers & Sustainability
Conflict Minerals Policy
Supplier Inquiry Form




News & Media
Blog
Patient Stories






Careers at Mallinckrodt
Community Outreach
Investor Relations










        Matthew HarbaughExecutive Vice President and Chief Financial Officer





Matthew Harbaugh is executive vice president and chief financial officer at Mallinckrodt Pharmaceuticals. He has executive responsibility for finance, procurement and information technology. Mr. Harbaugh is a member of Mallinckrodt’s executive committee.
Mr. Harbaugh has more than 20 years of experience in controllership, corporate finance, business development, financial planning and analysis, and investor relations.
Previously, Mr. Harbaugh served as the chief financial officer and interim president of the pharmaceuticals division of Covidien. He has worked as a lead finance executive at Cerberus Capital Management, L.P., a New York-based private equity firm. He also spent nearly 10 years at Monsanto, where he held several positions, including corporate finance director, investor relations, and finance director/chief financial officer for the company’s southern Argentine/Chilean and Canadian operations via two expatriate assignments.
Mr. Harbaugh holds a bachelor’s degree in finance from Saint Louis University and an MBA from Northwestern University.
Back












Building On Our Heritage
Nearly 150 years of quality, integrity and service.

Learn More






Our Culture
From philanthropic efforts to advocacy initiatives, we are living our hallmarks throughout our communities.

Learn How






















Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version















MNK Matthew K. Harbaugh Insider Trades for Mallinckrodt PLC


































Bulletin






Investor Alert





















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Mallinckrodt PLC

                  NYSE: MNK
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Mallinckrodt PLC



After Hours
 --Quotes are delayed by 20 min
Jul 28, 2017, 6:20 p.m.


MNK

/quotes/zigman/18081586/composite


$
46.06




Change

+0.16
+0.36%

Volume
Volume 17,225
Quotes are delayed by 20 min








/quotes/zigman/18081586/composite
Today's close

$
			46.60
		


$
				45.90
			
Change

-0.70
-1.50%





Day low
Day high
$45.60
$46.95










52 week low
52 week high

            $38.80
        

            $85.83
        


















Insider Activity


Individual




Matthew K. Harbaugh



Mr. Matthew K. Harbaugh is Chief Financial Officer & Senior Vice President at Mallinckrodt Plc, Chief Operating Officer at Mobile Technologies LLC, and Chief Financial Officer & Senior Vice President at Mallinckrodt Brand Pharmaceuticals, Inc. He is on the Board of Directors at Reading Is Fundamental, Inc.
Mr. Harbaugh was previously employed as President-Pharmaceuticals by Covidien Plc, Chief Investment Officer by Innovation Works, Inc., Chief Financial Officer & Customer Operations Lead by Monsanto Canada, Inc., Finance Director by Monsanto Co., Investment Banker by PNC Capital Markets LLC, and Regional Business Manager by Enterprise Rent-A-Car Co.
He received his undergraduate degree from St. Louis University, a graduate degree from Northwestern University, and an MBA from Northwestern University.



Transactions


Date
Shares
Transaction
Value





07/01/2017
1,620


 
Derivative/Non-derivative trans. at $44.81 per share.


72,593


03/10/2017
600


 
Acquisition at $49.19 per share.


29,514


01/04/2017
724


 
Derivative/Non-derivative trans. at $53.19 per share.


38,510


01/03/2017
1,718


 
Award at $0 per share.


0


01/03/2017
13,293


 
Award at $0 per share.


0


01/02/2017
4,334


 
Derivative/Non-derivative trans. at $49.82 per share.


215,920


01/02/2017
10,864


 
Award at $0 per share.


0


12/03/2016
297


 
Derivative/Non-derivative trans. at $53.61 per share.


15,923


07/01/2016
1,460


 
Derivative/Non-derivative trans. at $61.84 per share.


90,287


05/10/2016
500


 
Acquisition at $59.37 per share.


29,685


02/09/2016
1,300


 
Acquisition at $63 per share.


81,900


01/04/2016
809


 
Award at $0 per share.


0


01/04/2016
7,575


 
Award at $0 per share.


0


01/02/2016
669


 
Derivative/Non-derivative trans. at $74.63 per share.


49,928


12/04/2015
240


 
Acquisition at $73.54 per share.


17,649


12/03/2015
260


 
Acquisition at $74.05 per share.


19,253


12/01/2015
1,009


 
Derivative/Non-derivative trans. at $71.48 per share.


72,124


06/02/2015
1,000


 
Disposition at $130.02 per share.


130,020


06/02/2015
2,123


 
Disposition at $129.29 per share.


274,483


06/01/2015
18,983


 
Disposition at $128.5 per share.


2,439,316


06/01/2015
19,500


 
Derivative/Non-derivative trans. at $33.67 per share.


656,565


06/01/2015
14,951


 
Derivative/Non-derivative trans. at $31.12 per share.


465,275


06/01/2015
3,166


 
Derivative/Non-derivative trans. at $34.5 per share.


109,227


02/01/2015
127


 
Derivative/Non-derivative trans. at $105.99 per share.


13,461


01/02/2015
310


 
Derivative/Non-derivative trans. at $96.96 per share.


30,058


01/02/2015
3,827


 
Award at $0 per share.


0


12/03/2014
260


 
Acquisition at $74.05 per share.


19,253


12/03/2014
297


 
Derivative/Non-derivative trans. at $91.24 per share.


27,099


12/01/2014
2,085


 
Derivative/Non-derivative trans. at $88.22 per share.


183,939


02/01/2014
127


 
Derivative/Non-derivative trans. at $57.83 per share.


7,345


12/03/2013
297


 
Derivative/Non-derivative trans. at $51.54 per share.


15,308


12/01/2013
2,195


 
Derivative/Non-derivative trans. at $51.96 per share.


114,053


11/21/2013
3,600


 
Award at $0 per share.


0


11/21/2013
3,681


 
Award at $0 per share.


0


07/01/2013
8,750


 
Award at $0 per share.


0


06/28/2013
12,322


 
Award at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Mark C. Trudeau 
President, Chief Executive Officer & Director




Dr. Frank  Scholz 
Senior Vice President-Global Operations




Mr. Matthew K. Harbaugh 
Chief Financial Officer & Senior Vice President




Dr. Steven  Romano 
Chief Scientific Officer & Senior Vice President




Ms. Karen  Sheehy 
Chief Compliance Officer




Mr. Hugh M. Oneill 
President-Specialty Pharmaceuticals & Senior VP




Dr. Gary M. Phillips 
Chief Strategy Officer & Senior Vice President




Ms. Kathleen A. Schaefer 
Vice President & Controller




Mr. Coleman N. Lannum 
Senior Vice President-Investor Strategy




Ms. Meredith B. Fischer 
Chief Public Affairs Officer




Ms. Rhonda  Sciarra 
Manager-Corporate Communications




Mr. Ian J. Watkins 
Chief Human Resources Officer & Senior VP




Mr. Kenneth L. Wagner 
Secretary & Vice President




Mr. Michael-Bryant  Hicks 
Senior Vice President & General Counsel




Mr. Melvin D. Booth 
Chairman




Mr. Joseph A. Zaccagnino 
Independent Director




Dr. Kneeland C. Youngblood 
Independent Director




Ms. Diane H. Gulyas 
Independent Director




Mr. J. Martin Carroll 
Independent Director




Mr. David R. Carlucci 
Independent Director




Ms. JoAnn A. Reed 
Independent Director




Mr. Angus C. Russell 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




10:54 PM EDT
July 28, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
9:16pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
7:39pBarron's Buzz: Robo 2.0, Facebook and Twitter, Trading On News
7:29pA Wild Week in Washington 
6:32pThe dark side of cruises
6:32pThe highest paid athletes in the world, in one chart
6:31pO.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family
6:31p Trump to Police: 'Don't Be Too Nice'
6:31pHere are 10 co-workers you should avoid like the plague — especially in meetings
6:29pTop 10 most annoying people you may want to unfriend on Facebook 
6:29pThis is one person you should never unfriend on Facebook...
6:29p3 horrible ways typos could alter the course of your life
6:27pPaint your bathroom this color and boost your home’s selling price by $5,400
6:27pAmericans’ new badge of honor: ‘I was blocked by a celebrity!’
6:27p5 weird things I found out about America in my first 24 hours 
6:14pBeyond Tesla: 7 stocks driving the autonomous car revolution
6:14pThese 7 highly taxed companies need Congress to finally act on tax reform
6:11pWatch out: ‘Kids’ are making the most money in this stock market 
6:10p7 real ways for millennials to save money (not by brownbagging and skipping Starbucks)
6:09p‘Game of Thrones’: This computer model predicts who will be killed off — or survive
6:09pThis basic balanced index fund is beating the hedge fund averages
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,830.31

+33.76
+0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,374.68

-7.51
-0.12%





s&p 500

/quotes/zigman/3870025/realtime
2,472.10

-3.32
-0.13%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft


















Matthew K. Harbaugh - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In



















Matthew K. Harbaugh
Executive Vice President and Chief Financial Officer at Mallinckrodt


View Full Profile
Are you Matthew K. Harbaugh? Claim your profile


 


Sign up for Equilar Atlas and view Matthew K. Harbaugh's full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Matthew K. Harbaugh's  network and community.
												FOLLOW changes in Matthew K. Harbaugh's employment and money-in-motion.
												CONNECT with Matthew K. Harbaugh through your network of contacts.
												








Matthew K. Harbaugh's Executive Work History


Current


Executive Vice President and Chief Financial Officer, 
Mallinckrodt


Past
To view Matthew K. Harbaugh's complete executive work history, sign up now
Age
46

 
 






Sign up for Equilar Atlas and view Matthew K. Harbaugh's full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Matthew K. Harbaugh. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Matthew K. Harbaugh's  network and community.
												FOLLOW changes in Matthew K. Harbaugh's employment and money-in-motion.
												CONNECT with Matthew K. Harbaugh through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Matthew K. Harbaugh


















Matthew K. Harbaugh's Connections (32)





Sign up now to view Matthew K. Harbaugh's 32 connections »









Joseph A. Zaccagnino
Board Member, Mallinckrodt









Virgil D. Thompson
Former Board Member, Savient Pharmaceuticals, Inc.









Don M. Bailey
Board Member, Asterias Biotherapeutics, Inc.









David R. Carlucci
Board Member, Mallinckrodt









Steve R. Carchedi
Former Senior Vice President and President, Commercial Operations, North America, Mallinckrodt









Kneeland C. Youngblood
Board Member, Mallinckrodt









Terrance L. Carlson
Former Senior Vice President, General Counsel and Corporate Secretary, Medtronic plc









Melvin D. Booth
Chairman of the Board, Mallinckrodt









Angus C. Russell
Chairman, Revance Therapeutics, Inc.









Frank Scholz
Senior Vice President, Global Operations, Mallinckrodt








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Carl G. Annessa
EVP and COO, Hornbeck Offshore Services, Inc.









Elon R. Musk
CEO and Chairman, Tesla









Michael C. Montgomery
Board Member, NMI Holdings, Inc.












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

ï¿½ 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993















Matthew K. Harbaugh: Executive Profile & Biography - Bloomberg









































  





















































































July 28, 2017 10:54 PM ET
Pharmaceuticals

Company Overview of Mallinckrodt Public Limited Company



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Matthew K. Harbaugh  Chief Financial Officer and Executive Vice President, Mallinckrodt Public Limited CompanyAgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 2 different industries.47$3,967,650As of Fiscal Year 2016
Background

		Mr. Matthew K. Harbaugh serves as the Chief Financial Officer and Executive Vice President of Mallinckrodt public limited company. Mr. Harbaugh served as  Senior Vice President at Mallinckrodt public limited company. Mr. Harbaugh served as Chief Financial Officer and Vice President of Shared Services at Mallinckrodt, LLC. He served as the Chief Financial Officer of the pharmaceuticals business at Covidien plc and also served as Interim President of its pharmaceutical ... segment from November 2010 to January 2012. Before joining Covidien, he worked at Cerberus Capital Management, L.P., a New York-based private equity firm, where he was lead finance executive. Prior to Cerberus, he worked at Monsanto for nearly 10 years as Corporate Finance Director in St. Louis; Finance Director (Chief Financial Officer) and Commercial Grain Trading Lead - Latin America South, in Buenos Aires, Argentina; Manager of Investor Relations in St. Louis and Chief Financial Officer and Customer Operations Lead - Monsanto Canada, in Winnipeg, Manitoba. He served as a Director of Mallinckrodt plc from June 17, 2013 to June 28, 2013. Mr. Harbaugh holds a Bachelor’S Degree in Finance from St. Louis University and a Master’S Degree in Business Administration from the Kellogg Graduate School of Management at Northwestern University.Read Full Background




Corporate Headquarters
Perth HouseChesterfield, Derbyshire S41 8NDUnited KingdomPhone: 44 4246 263 051Fax: --
Board Members Memberships
				There is no Board Members Memberships data available.
				Education
Bachelor's Degree Saint Louis UniversityMaster's Degree J.L. Kellogg School of Management, Northwestern University
Other Affiliations
Mallinckrodt LLCSaint Louis UniversityJ.L. Kellogg School of Management, Northwestern UniversityCovidien plc


Annual Compensation
Salary$581,154Total Annual Compensation$581,154
Stocks Options
Restricted Stock Awards$1,661,817All Other Compensation$67,276Exercisable Options$70,225Exercisable Options Value$1,791,578Unexercisable Options$95,110Unexercisable Options Value$578,732Total Value of Options$2,370,309Total Number of Options$165,335
Total Compensation
Total Annual Cash Compensation$1,205,830Total Short Term Compensation$581,154Other Long Term Compensation$1,729,093Total Calculated Compensation$3,967,650




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONNamePosition/CompanyCompensationPaul V. Campanelli Chief Executive Officer, President and DirectorEndo International plc$987.0KPeter J. Arduini President, CEO & DirectorIntegra LifeSciences Holdings Corporation$878.8KJames C. Mullen CEO & Executive DirectorPatheon N.V.$1.4MRajat  Rai Chief Executive OfficerAkorn, Inc.$824.0KTimothy P. Walbert Chairman, President & Chief Executive OfficerHorizon Pharma Public Limited Company$951.0KCompensation as of Fiscal Year 2016.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Mallinckrodt Public Limited Company, please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close


























